WHO Releases Global Tuberculosis Report 2012

Click here to read full report.

The WHO released the Global Tuberculosis Report 2012 today. The main take home points are:

  • In the space of 17 years, 51m people were successfully treated for TB saving 20m lives.
  • TB rates worldwide are decreasing but the overall burden remains huge with drug-resistance becoming more and more of a challenge. Asia is the hardest hit region with the largest numbers of TB cases with the majority in China and India. Africa and Europe are not seeing rates decline as quickly as other regions.
  • The new statistics highlight the urgent need for new tools, such as new drugs, new diagnostics, and new vaccines ,to significantly impact the burden of TB and reach the goals outlined in the Global Plan to Stop TB.
  • Funding for tuberculosis research and implementation needs to increase to address this disease that is still killing over a million people a year. Current funding levels are just inadequate.

Additional Coverage:

In new report, WHO warns global fight against TB now at a crossroads

TB rates down, but its ‘global burden’ remains huge, WHO reports

World TB cases fall, but drug-resistance a worry: WHO

Tuberculosis effort in real danger – WHO

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...